Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Losartan
34 records.
Article ID PMID Source Title Publish Year
A00329 35133671 Hepatology Randomized placebo-controlled trial of losartan for pediatric NAFLD. 2022 Details
A01605 34681219 Pharmaceuticals (Basel) Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. 2021 Details
A02473 34360607 Int J Mol Sci Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1α in a Murine Model of NAFLD. 2021 Details
A09801 31604805 J Lipid Res Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis. 2019 Details
A13409 29992039 Pilot Feasibility Stud A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. 2018 Details
A15287 28986475 Drug Metab Dispos Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis. 2017 Details
A15877 28676018 Curr Vasc Pharmacol Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? 2018 Details
A16398 28419124 PLoS One A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. 2017 Details
A16707 28231800 Lipids Health Dis Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. 2017 Details
A17620 27712037 J Biochem Mol Toxicol In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. 2016 Details
A19020 26817117 Eksp Klin Gastroenterol [COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE]. 2015 Details
A22495 24517411 Metab Syndr Relat Disord Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. 2014 Details
A22931 24197250 J Gastroenterol Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. 2013 Details
A23157 23997767 Int J Endocrinol Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). 2013 Details
A23310 23875703 Clin Sci (Lond) Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury. 2014 Details
A24014 23301938 J Gastroenterol Hepatol Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. 2013 Details
A25518 21748770 Hepatology Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. 2011 Details
A25872 21372165 Am J Physiol Gastrointest Liver Physiol Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. 2011 Details
A26788 19782079 Gastroenterology Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. 2009 Details
A27065 19230890 Atherosclerosis Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. 2009 Details
A27214 18972077 Adv Ther Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? 2008 Details
A27993 16768124 Nihon Rinsho [Clinical utility of angiotensin II receptor antagonist]. 2006 Details
A31978 29404501 Hepatol Commun Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. 2017 Details
A32601 28029729 Hepatol Res Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. 2017 Details
A35917 19416517 BMC Res Notes Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. 2009 Details
A36634 17565640 J Gastroenterol Hepatol Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. 2007 Details
A36711 17410287 J Gastrointestin Liver Dis Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. 2007 Details
A37100 16482638 World J Gastroenterol Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. 2006 Details
A37556 15382153 Hepatology Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. 2004 Details
A42202 35247475 J Ethnopharmacol The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. 2022 Details
A45938 21953015 Hepatology Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? 2011 Details
A48139 21800342 Hepatology Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis. 2011 Details
A50747 35279807 Indian J Gastroenterol Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. 2022 Details
A51490 24918049 FEBS Open Bio Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. 2014 Details